EGFR and non-small cell lung carcinoma: TP53 co-mutation is frequent in EGFR-mutant NSCLC and has been consistently associated with more aggressive disease biology and inferior outcomes under EGFR-TKIs across multiple cohorts and meta-analyses (19–22).